Supernus Pharmaceuticals (SUPN) Net Income towards Common Stockholders (QoQ) (2011 - 2025)
Supernus Pharmaceuticals (SUPN) Net Income towards Common Stockholders (QoQ) (2011 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn |
| 10 | Supernus Pharmaceuticals | 2.72 Bn | 2.34 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 90.90% |
| Sep 30, 2025 | -300.53% |
| Jun 30, 2025 | 290.23% |
| Mar 31, 2025 | -177.16% |
| Dec 31, 2024 | -60.23% |
| Sep 30, 2024 | 93.66% |
| Jun 30, 2024 | 13,817.48% |
| Mar 31, 2024 | -87.83% |
| Dec 31, 2023 | 107.35% |
| Sep 30, 2023 | -1,831.80% |
| Jun 30, 2023 | -104.88% |
| Mar 31, 2023 | -33.56% |
| Dec 31, 2022 | 1,358.43% |
| Sep 30, 2022 | -77.76% |
| Jun 30, 2022 | -69.30% |
| Mar 31, 2022 | 949.26% |
| Dec 31, 2021 | -88.67% |
| Sep 30, 2021 | -9.12% |
| Jun 30, 2021 | 316.68% |
| Mar 31, 2021 | -81.49% |